This 2022 randomized, double-blind, placebo-controlled trial published in Scientific Reports (DOI: 10.1038/s41598-021-04397-z, PMID: 34997178) evaluated the effects of alpha-lipoic acid (ALA) supplementation in 92 women with episodic migraines. Over 3 months, participants receiving 300 mg/day of ALA experienced significant reductions in headache frequency, severity, and duration, along with decreased levels
